Good compliance · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in good compliance compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Patient quality of life · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Amount of analgesia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Relief of pain · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine showed no clear difference in treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in treatment withdrawal for any reason compared with active comparators (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Pregabalin probably leads to higher treatment withdrawal for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in treatment withdrawal compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (adverse effect) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher treatment withdrawal (adverse effect) (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review